Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Editas Medicine, Inc. (EDIT)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
12.24+0.08 (+0.66%)
At close: 04:00PM EDT
12.32 +0.08 (+0.65%)
After hours: 07:23PM EDT
Advertisement

Yahoo Finance will soon be upgrading our Conversations message board platform to provide a better experience for our users. Only comments published since April 21, 2021 will be visible on Yahoo Finance after the upgrade. If you wish to download and save any of your older comments, please submit a request via the Privacy Dashboard by no later than Sept. 30.

Sign in to post a message.
  • L
    LostAllMyShirts
    Have a look at the pages of PATENTS owned by Editas , thats on top of the Exclusive License they have with
    BROAD Institute ;

    https://patents.justia.com/assignee/editas-medicine-inc?page=1

    This company has to be the Bargain of the year.
    Bullish
  • m
    mark
    we need a miracle lads
  • K
    Kyle
    Wow.......well, short interest over 23% of float. The last time the stock ran up to 99, the short interest was less than 20%. If this train can ever get started.....watch out. Consider this, EDIT owns 100% of their SCD and Beta Thal treatments. CRSP sold 10% of their ownership of their SCD and Beta Thal treatments for $900M to Vertex, who already owned 50% of it. What type of cash could EDIT get for 10-50% ownership for their treatments? I'd be scared to be short this stock if any kind of partnership comes out between EDIT and any major pharmaceutical company.
  • K
    Kyle
    I highly recommend listening to the MS 20th Annual Healthcare Conference webcast from Sept 12. I think it provides a lot of clarity as to why Edit 101 was done, is still on going, and what has/will be learned by this trial. As a shareholder, it was nice to hear some intelligent, coherent explanation of what is going on at Editas.
  • J
    Jim
    Another day, another week another year in the pits with the new economy of guess who. Just my feelings about this.
  • i
    iamaverb
    Editas has its new August presentation online and it appears progress is being made in the clinic.
  • i
    iamaverb
    REGN is the reason I am in EDIT. Eylea was first approved in 2011 and the rest is history.
  • i
    iamaverb
    $BEAM conversation
    The market is a fickle mistress. Intellia announces new promising results and all things CRISPR falls in unison. $NTLA $EDIT $BEAM $VERV
  • D
    Dan
    Added more
  • L
    LostAllMyShirts
    BROAD is expanding Broadly. As EDITAS have excusive license with BROAD I hope this will be good for them;
    https://endpts.com/sp/the-factors-driving-a-rapid-evolution-of-gene-cell-therapy-and-car-t-clinical-research-in-apac/
    Bullish
  • J
    Jim
    Back for another week of watching the decline of nearly everything. The real sad reality is that it did not have to go or be this way. This the new green deal Biden promised he would deliver and he did. Elections make a real living difference and we the people are living it. Personally with much regret.
  • g
    grayfoxroving
    I have kept quiet while watching all the ones pumping newsletters and other stocks but it's the weekend and I believe that most of us that hold EDIT, many dumpers here do not own it but want it to go down so they can, we did not buy with any expectations of a fast buck. It takes time to develop something as technologically advanced as genetic engineering but once the comes into the mainstay health treatments then what we believe in will be proven true. I personally wish that EDIT had concentrated on sickle cell anemia instead of Lebers but EDIT made the decision. Sickle cell could be a huge market, huge interest from big pharma, Lebers just a spark in the pan. My position in EDIT is perhaps one-half of one percent of my holdings but still, I find it an intriguing investment, not one for anyone having it as a core holding, but a hopefully one day company on the forefront o genetic engineering development. For now, if you have cash, keep it safe. Soon, a month before the November elections, if it looks like we will have a new Congress to temper back the current Administration then all stocks will rise. Even then, buy large cap stocks that have sales of somethings that people need, food, cars, electricity, and also items already financed for defense such as drones, rockets, advanced technology for warfare. We as a nation have to get back to basics.
  • i
    iamaverb
    $BEAM conversation
    Todays short interest
    $BEAM 12,133,589 Down 1m shares from the high.
    $VERV 9,593,086 Down 400k shares from the high.
    $EDIT 16,250,239 Down 500k shares from the high.

    These numbers bode well if you are thinking short squeeze on news.
  • S
    Sean
    Keep your powder dry guys. Next Weds 7th at 1:15 pm is the Wells Fargo Healthcare Conference
  • i
    iamaverb
    $BEAM conversation
    Here is a little deep dive into $EDIT $BEAM $VERV.
    Editas was founded (perhaps a little too early) in 2013 by Harvard alumni Feng Zhang, Keith Joung, David Liu, and George Church. Editas recently won the patent decision and controls the almost exclusive rights to
    Cas-9 and Cas-12a.

    Beam was incorporated in 2017 and founded by Feng Zhang, Keith Joung, and Davis Liu.
    Beam created a license agreement with Editas in 2018 and Editas received royalties and stock in Beam, which they sold when Beam IPOed.

    Keith Joung founded Verve and they incorporated in 2018. Verve has a license directly with Harvard/MIT for CRISPR Cas-9 and Cas12a, bypassing Editas.
    Verve has a base editing license with Beam for certain diseases.

    John Evans, the CEO of Beam since 2017, was once a partner in Arch Venture Partners that initially funded Beam and Verve, and is now a special advisor to Verve. Evans left Arch in 2021 to devote full-time attention to running Beam.

    Verve's first clinical trial is hoping to develop a one-and-done treatment to fight high cholesterol, which takes on the #1 best-selling drug ever, Pfizer's Lipitor. Pfizer also has a huge collaboration with Beam worth up to $1.35 billion, perhaps more.

    All in all, it is one big family of CRISPR 1.0 and 2.0 founders with the $262 billion giant Pfizer lurking over their shoulders and in the background.
  • L
    L.
    Once the GBT buyout is finalized (probably not much longer), we may see some of those $$$ coming into stocks like EDIT.
  • C
    Carmean
    Are you guys still in EDIT? They just got featured on the watchlist at (http://market-engross.club)
  • J
    Jim
    It seems irrational to be so far down in less than two years, from so well to so poor. (state of America)
  • W
    Woodie
    EDIT is my only stock green today.
    Bullish
  • t
    thomas
    Tanking AH lol
    Bearish
Advertisement
Advertisement